205 results on '"Lebbe, Celeste"'
Search Results
2. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
3. Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline – update 2024
4. Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma
5. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024
6. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
7. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
8. BRAF and MEK inhibitors rechallenge after an adverse drug reaction in patients with cancer: A pharmacovigilance cohort study
9. When to stop immunotherapy for advanced melanoma: the emulated target trials
10. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
11. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database
12. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II
13. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I
14. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.
15. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
16. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
17. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
18. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
19. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023
20. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023
21. Hyperprogression in advanced melanoma is not restricted to immunotherapy
22. Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
23. Biomarqueurs prédictifs de la réponse à l’immunothérapie dans les mélanomes
24. Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease
25. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
26. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort
27. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review
28. Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors
29. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial
30. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases
31. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022
32. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
33. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
34. PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study
35. Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort
36. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
37. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
38. Un exemple de réorganisation dans le fonctionnement d’un Centre d’investigations cliniques en période de confinement national suite à la pandémie COVID-19
39. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
40. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
41. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
42. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
43. Hematological immune related adverse events after treatment with immune checkpoint inhibitors
44. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
45. Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal
46. Deep cutaneous fungal infections in solid-organ transplant recipients
47. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention
48. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
49. Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
50. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.